Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy

The Effect of Radiation Therapy on Tumor Immunity

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02310594

Enrollment

139

Registered

2014-12-08

Start date

2010-07-08

Completion date

2022-08-09

Last updated

2022-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm

Brief summary

This research trial studies the effect of radiation therapy on tumor immunity. Standard radiation therapy destroys tumor cells. In response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective in shrinking tumor tissue. Collecting samples of blood from patients before, during, and after radiation therapy to study in the laboratory may help doctors learn more about the effects of radiation therapy on anti-tumor response.

Detailed description

PRIMARY OBJECTIVES: I. To assess the effect of radiation therapy on tumor immunity. OUTLINE: Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.

Interventions

OTHERcytology specimen collection procedure

Undergo blood sample collection

OTHERlaboratory biomarker analysis

Correlative studies

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed and dated Institutional Review Board (IRB)-approved Informed Consent form for the study * Received an explanation of the study, including satisfactory answers to all questions related to the proposed research * Is undergoing physician directed radiation treatment

Exclusion criteria

* The potential Subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate Informed Consent form

Design outcomes

Primary

Measure	Time frame
Outcome measures include changes in tumor-specific immune responses and general immune signature in patients undergoing Radiation Treatment. Reportable endpoints are absolute values of and changes in innate & adaptive immune cells and serum markers.	The time line of interest covers a baseline, pre-treatment sample as well as mid-treatment and a post-treatment, follow-up sample at 3 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026